Finance

Lists
URGN:NASDAQ
Urogen Pharma Ltd
36,61 $
+0,08%
(+0,030) 1D
36,61 $
0,00% (0,00)
After hours
Closed: 15 հոկ, 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for URGN...
Open
37,04 $
High
38,37 $
Low
36,27 $
Mkt. cap
1,79 մլրդ
Avg. vol.
903,86 հզր
Volume
0,00
52-wk high
50,81 $
52-wk low
16,36 $
EPS
-1,98 $
Beta
1,57
Shares outstanding
48,88 մլն
No. of employees
300
Open
37,04 $
High
38,37 $
Low
36,27 $
Mkt. cap
1,79 մլրդ
Avg. vol.
903,86 հզր
Volume
0,00
52-wk high
50,81 $
52-wk low
16,36 $
EPS
-1,98 $
Beta
1,57
Shares outstanding
48,88 մլն
No. of employees
300
News stories
From web sources and news partners
About Urogen Pharma Ltd
CEO-
Employees300
Founded2004
HeadquartersՆյու Յորք, Նյու Յորք, Միացյալ Նահանգներ
Sector-
Websiteurogen.com
Analyst ratings
Based on 5 analysts giving stock ratings to URGN in the past 3 months
Strong buy
Buy
4
Hold
1
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for URGN in the last 3 months.
Highest
Current 36,61 $
75,00 $ (+104,86%)
Average
60,20 $ (+64,44%)
Lowest
48,00 $ (+31,11%)
Analyst
Recommendation
Action
Price target
Projected
Date
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
75,00 $
+104,9%
08/21/2026
Leland Gershell
Oppenheimer
Buy
Reiterated
60,00 $
+63,9%
08/06/2026
Paul Choi
Goldman Sachs
Hold
Maintained
48,00 $
+31,1%
08/05/2026
Michael Schmidt
Guggenheim
Buy
Maintained
58,00 $
+58,4%
08/05/2026
Tara Bancroft
TD Cowen
Buy
Reiterated
60,00 $
+63,9%
08/05/2026
Unknown Analyst
Guggenheim
Buy
Maintained
32,00 $
-12,6%
06/03/2026
Kevin DeGeeter
Ladenburg Thalmann & Co.
Buy
Initiated
43,00 $
+17,5%
05/11/2026
Kelsey Goodwin
Piper Sandler
Buy
Maintained
40,00 $
+9,3%
04/20/2026
Amin Makarem
Jefferies
Buy
Initiated
40,00 $
+9,3%
04/09/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
27,48 մլն
37,84 մլն
50,96 մլն
72,46 մլն
Cost of goods sold
3,28 մլն
3,29 մլն
4,14 մլն
6,57 մլն
Cost of revenue
3,28 մլն
3,29 մլն
4,14 մլն
6,57 մլն
Research and development expenses
14,01 մլն
14,31 մլն
15,60 մլն
17,34 մլն
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
37,58 մլն
39,35 մլն
51,49 մլն
48,44 մլն
Operating expense
51,59 մլն
53,66 մլն
67,08 մլն
65,77 մլն
Total operating expenses
54,87 մլն
56,95 մլն
71,22 մլն
72,34 մլն
Operating income
-27,39 մլն
-19,12 մլն
-20,26 մլն
111,00 հզր
Other non operating income
-4,82 մլն
-4,66 մլն
-4,83 մլն
-4,89 մլն
EBT including unusual items
-34,40 մլն
-26,64 մլն
-28,35 մլն
-8,72 մլն
EBT excluding unusual items
-34,40 մլն
-26,64 մլն
-28,35 մլն
-8,72 մլն
Income tax expense
-1,05 մլն
-275,00 հզր
-4,77 մլն
5,63 մլն
Effective tax rate
3,06%
1,03%
16,83%
-64,54%
Other operating expenses
-
-
-
-
Net income
-33,35 մլն
-26,36 մլն
-23,57 մլն
-14,35 մլն
Net profit margin
-121,34%
-69,68%
-46,26%
-19,81%
Earnings per share
-0,69
-0,53
-0,47
-0,28
Interest and investment income
1,18 մլն
908,00 հզր
931,00 հզր
946,00 հզր
Interest expense
-3,37 մլն
-3,77 մլն
-4,18 մլն
-4,89 մլն
Net interest expenses
-2,20 մլն
-2,86 մլն
-3,25 մլն
-3,94 մլն
Depreciation and amortization charges
-
-
-
-
EBITDA
-27,31 մլն
-19,04 մլն
-20,19 մլն
189,00 հզր
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google Apps